Pharmacopsychiatry 2004-11-01

Neuropharmacology of the anxiolytic drug opipramol, a sigma site ligand.

W E Müller, B Siebert, G Holoubek, C Gentsch

Index: Pharmacopsychiatry 37 Suppl 3 , S189-97, (2004)

Full Text: HTML

Abstract

Although opipramol is structurally related to imipramine, it does not represent a tricyclic antidepressant drug as it does not inhibit the neuronal uptake of norepinephrine and/or serotonin. Unlike imipramine it is a rather potent sigma ligand with modest subclass selectivity which is similar in vitro as well as ex vivo. Opipramol is active in several behavioural paradigms indicative of anxiolytic properties at doses (1-10 mg/kg), which are also needed to occupy sigma binding sites. Somewhat higher doses (10-20 mg/kg) are needed for "antidepressant like" effects. The data allow the conclusion that interaction with sigma sites is involved in the anxiolytic and antidepressant effects of opipramol albeit a contribution of its weaker D (2)-antagonistic and 5-HT2-antagonistic properties cannot be totally be excluded.

Related Compounds

  • OPIPRAMOL DI...

Related Articles:

Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.

2006-01-01

[World J. Biol. Psychiatry 7(4) , 261-4, (2006)]

In vitro studies of DNA damage caused by tricyclic antidepressants: a role of peroxidase in the side effects of the drugs.

2010-09-20

[Chem. Res. Toxicol. 23(9) , 1497-503, (2010)]

Opipramol improves subjective quality of sleep the night prior to surgery: confirmatory testing of a double-blind, randomized clinical trial.

2011-01-01

[Neuropsychobiology 64(1) , 24-31, (2011)]

[Opipramol in anxiety and somatoform disorders. Results of a controlled study].

1998-12-01

[Fortschr. Neurol. Psychiatr. 66 Suppl 1 , S21-4, (1998)]

[Opipramol in behavioral pharmacologic anxiety and depression models].

1998-12-01

[Fortschr. Neurol. Psychiatr. 66 Suppl 1 , S17-20, (1998)]

More Articles...